Individuals | 11 223 | 2444 | 8779 | |
Female | 7003 (62.4) | 1637 (67.0) | 5366 (61.1) | <0.001 |
Age | 36 (29–41) | 35 (26–41) | 37 (30–42) | <0.001 |
18–25 years | 1761 (15.7) | 555 (22.7) | 1206 (13.7) | <0.001 |
26–35 years | 3406 (30.3) | 734 (30.0) | 2672 (30.4) | 0.709 |
36–45 years | 6056 (54.0) | 1155 (47.3) | 4901 (55.8) | <0.001 |
Marital status | | | | |
Unmarried | 3434 (30.6) | 928 (38.0) | 2506 (28.5) | <0.001 |
Married/registered partnership | 4717 (42.0) | 933 (38.2) | 3784 (43.1) | <0.001 |
Divorced/widowed | 1242 (11.1) | 223 (9.1) | 1019 (11.6) | <0.001 |
Other/missing | 14 (0.1) | 5 (0.2) | 9 (0.1) | 0.203 |
Region of residency | | | | |
Capital | 3262 (29.1) | 888 (36.3) | 2374 (27.0) | <0.001 |
Zealand | 1734 (15.5) | 236 (9.7) | 1498 (17.1) | <0.001 |
North Denmark | 1094 (9.7) | 189 (7.7) | 905 (10.3) | <0.001 |
Central Denmark | 2595 (23.1) | 473 (19.4) | 2122 (24.2) | <0.001 |
Southern Denmark | 2520 (22.5) | 654 (26.8) | 1866 (21.3) | <0.001 |
Missing | 18 (0.2) | n<5 | | |
Years since first asthma drug dispensing (any time before index date) | 7 (4–13) | 9 (4–14) | 7 (4–12) | <0.001 |
Concurrent asthma medication | | | | |
ICS | | | | |
No use | 1735 (15.5) | 200 (8.2) | 1535 (17.5) | <0.001 |
Low dose | 5696 (50.8) | 1208 (49.4) | 4488 (51.1) | 0.143 |
Medium/high dose | 3792 (33.8) | 1036 (42.4) | 2756 (31.4) | <0.001 |
LABA | 6296 (56.1) | 1790 (73.2) | 4506 (51.3) | <0.001 |
LTRA | 1876 (16.7) | 732 (30.0) | 1144 (13.0) | <0.001 |
LAMA | 344 (3.1) | 126 (5.2) | 218 (2.5) | <0.001 |
SABA canisters | | | | |
0–<3 | 4690 (41.8) | 978 (40.0) | 3712 (42.3) | 0.046 |
3–<12 | 4749 (42.3) | 1145 (46.8) | 3604 (41.1) | <0.001 |
≥12 | 1784 (15.9) | 321 (13.1) | 1463 (16.7) | <0.001 |
Co-medication | | | | |
Antibiotics | 8009 (71.4) | 1731 (70.8) | 6278 (71.5) | 0.511 |
Antihistamines | 3655 (32.6) | 1042 (42.6) | 2613 (29.8) | <0.001 |
Nasal corticosteroids | 2983 (26.6) | 942 (38.5) | 2041 (23.2) | <0.001 |
Antidepressants | 1628 (14.5) | 299 (12.2) | 1329 (15.1) | <0.001 |
Anti-acid drugs | 1813 (16.2) | 438 (17.9) | 1375 (15.7) | 0.008 |
Anti-obesity drugs | 355 (3.2) | 57 (2.3) | 298 (3.4) | 0.007 |
Antidiabetic drugs, excluding insulins | 157 (1.4) | 36 (1.5) | 121 (1.4) | 0.698 |
Bisphosphonates | 16 (0.1) | n<5 | | 0.762 |
Asthma-related ED visits | | | | |
1 | 431 (3.8) | 147 (6.0) | 284 (3.2) | <0.001 |
2 | 73 (0.7) | 30 (1.2) | 43 (0.5) | <0.001 |
≥3 | 47 (0.4) | 13 (0.5) | 34 (0.4) | 0.374 |
Asthma-related hospitalisations | | | | |
1 | 1097 (9.8) | 336 (13.7) | 761 (8.7) | <0.001 |
2 | 276 (2.5) | 133 (5.4) | 143 (1.6) | <0.001 |
≥3 | 141 (1.3) | 70 (2.9) | 71 (0.8) | <0.001 |